ERBB2 and triple-negative breast carcinoma: Triple-negative breast cancer (TNBC) is characterized by younger age occurrence, higher rates of relapse, greater metastatic potential, and shorter overall survival compared with the hormone receptor-positive/human epidermal growth factor 2 receptor (HER2) negative (70% of patients) and HER2 positive (15%–20% of patients) phenotypes2,3.